Chronic myopathy due to immunoglobulin light chain amyloidosis

Molecular Genetics and Metabolism

Volumn 108, Issue 4, 2013, Pages 249-254

  Manoli, Irini ^a,b   Kwan, Justin Y ^c   Wang, Qian ^d   Rushing, Elisabeth J ^e   Tsokos, Maria ^f   Arai, Andrew E ^g   Burch, Warner M ^h   Dispenzieri, Angela ⁱ   McPherron, Alexandra C ^d   Gahl, William A ^a,b  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e UNIVERSITY OF ZURICH   (Switzerland)

^f NATIONAL CANCER INSTITUTE   (United States)

^g NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ MAYO CLINIC   (United States)

Author keywords

Amyloidosis; Muscle hypertrophy; Pax7; Satellite cells

Indexed keywords

BETA 2 MICROGLOBULIN; GADOLINIUM; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; PEGVISOMANT; TRANSCRIPTION FACTOR PAX7;

ABDOMINAL WALL MUSCULATURE; ADULT; AMYLOIDOSIS; ARM MUSCLE; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BICEPS BRACHII MUSCLE; BONE MARROW BIOPSY; CARDIOVASCULAR MAGNETIC RESONANCE; CARPAL TUNNEL SYNDROME; CASE REPORT; CLAUDICATION; DIASTOLIC DYSFUNCTION; DYSPHAGIA; DYSPNEA; ECHOCARDIOGRAPHY; ELECTRODIAGNOSIS; ELECTROMYOGRAM; ENDOMYSIUM; EXERCISE TEST; EXTRAOCULAR MUSCLE; FATIGUE; FEMALE; HEART EJECTION FRACTION; HUMAN; HUMAN TISSUE; HYPOPHYSIS DISEASE; IMMUNOFLUORESCENCE TEST; INFORMED CONSENT; MACROGLOSSIA; METABOLIC EQUIVALENT; MOTOR UNIT POTENTIAL; MUSCLE BIOPSY; MUSCLE HYPERTROPHY; MUSCLE TIGHTNESS; MYOPATHY; NERVE CONDUCTION; PAIN; PERIMYSIUM; PLASMA CELL; PRIORITY JOURNAL; SHOULDER GIRDLE; SLEEP DISORDERED BREATHING; TONGUE EDEMA;

ADULT; AMYLOIDOSIS; BONE MARROW TRANSPLANTATION; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MUSCULAR DISEASES; PARAPROTEINEMIAS; SATELLITE CELLS, SKELETAL MUSCLE; TRANSPLANTATION, AUTOLOGOUS;

EID: 84875249615     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2013.01.015     Document Type: Article

References (32)

1. Spuler S., Emslie-Smith A., Engel A.G. Amyloid myopathy: an underdiagnosed entity. Ann. Neurol. 1998, 43:719-728.
2. Mastaglia F.L., Ojeda V.J., Sarnat H.B., Kakulas B.A. Myopathies associated with hypothyroidism: a review based upon 13 cases. Aust. N. Z. J. Med. 1988, 18:799-806.
3. Schuelke M., Wagner K.R., Stolz L.E., Hubner C., Riebel T., Komen W., Braun T., Tobin J.F., Lee S.J. Myostatin mutation associated with gross muscle hypertrophy in a child. N. Engl. J. Med. 2004, 350:2682-2688.
4. Spuler S., Kalbhenn T., Zabojszcza J., van Landeghem F.K., Ludtke A., Wenzel K., Koehnlein M., Schuelke M., Ludemann L., Schmidt H.H. Muscle and nerve pathology in Dunnigan familial partial lipodystrophy. Neurology 2007, 68:677-683.
5. Dupre N., Chrestian N., Bouchard J.P., Rossignol E., Brunet D., Sternberg D., Brais B., Mathieu J., Puymirat J. Clinical, electrophysiologic, and genetic study of non-dystrophic myotonia in French-Canadians. Neuromuscul. Disord. 2009, 19:330-334.
6. Gahl W.A., Markello T.C., Toro C., Fajardo K.F., Sincan M., Gill F., Carlson-Donohoe H., Gropman A., Pierson T.M., Golas G., Wolfe L., Groden C., Godfrey R., Nehrebecky M., Wahl C., Landis D.M., Yang S., Madeo A., Mullikin J.C., Boerkoel C.F., Tifft C.J., Adams D. The National Institutes of Health Undiagnosed Diseases Program: insights into rare diseases. Genet. Med. 2012, 14:51-59.
7. Gahl W.A., Tifft C.J. The NIH Undiagnosed Diseases Program: lessons learned. JAMA 2011, 305:1904-1905.
8. Zhang J., George A.L., Griggs R.C., Fouad G.T., Roberts J., Kwiecinski H., Connolly A.M., Ptacek L.J. Mutations in the human skeletal muscle chloride channel gene (CLCN1) associated with dominant and recessive myotonia congenita. Neurology 1996, 47:993-998.
9. Gay S., Dupuis D., Faivre L., Masurel-Paulet A., Labenne M., Colombani M., Soichot P., Huet F., Hainque B., Sternberg D., Fontaine B., Gouyon J.B., Thauvin-Robinet C. Severe neonatal non-dystrophic myotonia secondary to a novel mutation of the voltage-gated sodium channel (SCN4A) gene. Am. J. Med. Genet. A 2008, 146:380-383.
10. Modi G. Cores in hypothyroid myopathy: a clinical, histological and immunofluorescence study. J. Neurol. Sci. 2000, 175:28-32.
11. Nagulesparen M., Trickey R., Davies M.J., Jenkins J.S. Muscle changes in acromegaly. Br. Med. J. 1976, 2:914-915.
12. Whitaker J.N., Hashimoto K., Quinones M. Skeletal muscle pseudohypertrophy in primary amyloidosis. Neurology 1977, 27:47-54.
13. Ringel S.P., Claman H.N. Amyloid-associated muscle pseudohypertrophy. Arch. Neurol. 1982, 39:413-417.
14. Roke M.E., Brown W.F., Boughner D., Ang L.C., Rice G.P. Myopathy in primary systemic amyloidosis. Can. J. Neurol. Sci. 1988, 15:314-316.
15. Simmons Z., Specht C.S. The neuromuscular manifestations of amyloidosis. J. Clin. Neuromuscul. Dis. 2010, 11:145-157.
16. Jennekens F.G., Wokke J.H. Proximal weakness of the extremities as main feature of amyloid myopathy. J. Neurol. Neurosurg. Psychiatry 1987, 50:1353-1358.
17. Chapin J.E., Kornfeld M., Harris A. Amyloid myopathy: characteristic features of a still underdiagnosed disease. Muscle Nerve 2005, 31:266-272.
18. Rajkumar S.V., Dispenzieri A., Kyle R.A. Monoclonal gammopathy of undetermined significance, Waldenstrom macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clin. Proc. 2006, 81:693-703.
19. Pepys M.B. Amyloidosis. Annu. Rev. Med. 2006, 57:223-241.
20. Kyle R.A., Gertz M.A. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin. Hematol. 1995, 32:45-59.
21. Kyle R.A., Bayrd E.D. Amyloidosis: review of 236 cases. Medicine (Baltimore) 1975, 54:271-299.
22. Gertz M.A. Immunoglobulin light chain amyloidosis, update on diagnosis, risk-stratification, and management. Am. J. Hematol. 2011, 86(2011):180-186.
23. Dispenzieri A., Lacy M.Q., Kyle R.A., Therneau T.M., Larson D.R., Rajkumar S.V., Fonseca R., Greipp P.R., Witzig T.E., Lust J.A., Gertz M.A. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J. Clin. Oncol. 2001, 19:3350-3356.
24. Scola R.H., Werneck L.C., Ramos C.S., Pasquini R., Graf H., Arruda W.O. Amyloidotic muscle pseudohypertrophy: case report. Arq. Neuropsiquiatr. 2001, 59:582-586.
25. Gertz M.A., Kyle R.A. Myopathy in primary systemic amyloidosis. J. Neurol. Neurosurg. Psychiatry 1996, 60:655-660.
26. Doriguzzi C., Mongini T., Troni W., Monga G. Early sarcolemmal dysfunction in skeletal muscle amyloidosis. J. Neurol. 1987, 234:52-54.
27. Delaporte C., Varet B., Fardeau M., Nochy D., Ract A. In vitro myotrophic effect of serum kappa chain immunoglobulins from a patient with kappa light chain myeloma and muscular hypertrophy. J. Clin. Invest. 1986, 78:922-927.
28. Seale P., Rudnicki M.A. A new look at the origin, function, and "stem-cell" status of muscle satellite cells. Dev. Biol. 2000, 218:115-124.
29. Schultz E., Jaryszak D.L., Valliere C.R. Response of satellite cells to focal skeletal muscle injury. Muscle Nerve 1985, 8:217-222.
30. O'Connor R.S., Pavlath G.K. Point: counterpoint: satellite cell addition is/is not obligatory for skeletal muscle hypertrophy. J. Appl. Physiol. 2007, 103:1099-1100.
31. McCarthy J.J., Esser K.A. Counterpoint: satellite cell addition is not obligatory for skeletal muscle hypertrophy. J. Appl. Physiol. 2007, 103:1100-1102. (discussion 1102-1103.).
32. Renault V., Thornell L.E., Eriksson P.O., Butler-Browne G., Mouly V. Regenerative potential of human skeletal muscle during aging. Aging Cell 2002, 1:132-139.